Brain-Amoebae
can cause extremely dangerous kinds of encephalitis and much more than 95
percent of the people who acquire these rare but devastating infections are
dead. Due to the high fatality rate, no specific effective treatment is
currently available for fighting these pathogens, However; scientists have now
developed some chemical compounds which show the potential effect at treatments in
the laboratory, as per a report in ACS Chemical Neuroscience.
Naegleria
fowleri and Balamuthia mandrillaris are two varieties of amoebae that trigger
primary amoebic meningoencephalitis and encephalitis
in granulomatous form. These are single-celled microorganisms that live in
water and soil and that can enter the body through the nose or open wounds. Such
pathogens can then spread to the central nervous system, whereby brain cells
are killed. Patients are given high doses of many different antimicrobial
agents in the very few cases that were successfully treated.
Such
medications, nevertheless, are usually lacking in specificity and can have
highly toxic effects. Ruqaiyyah Siddiqui and colleagues have turned to quinazolinones
to make progress towards a new drug. Such compounds function against such a
broad range of human targets, including bacteria, viruses, fungi, parasites, and
cancer, but were never evaluated against brain-eating amoebae.
The
scientists synthesized 34 new derivatives of quinazolinone and studied its
effects on N. Fowleri, B. Mandrillaire. Most of the new compounds have also
been successful in killing the micro-organisms and reducing the harm which
pathogens in a Petri dish can do to human cells. Attaching silver nanoparticles
to the derivatives in some cases enhanced the behavior. Chlorine, methyl, or
methoxy groups have been the most effective compounds and their toxicity to
human cells was low. The researchers claim that findings suggest that
quinazolinones are great candidates for experiments in drug
development.
Contact:
Amelia
David
Program
Manager
Drug
Discovery Congress 2020
drugchemistry@memeetings.com